Press Releases

Dec 26, 2018

FDA Approves VAXELIS™, Sanofi and Merck’s Pediatric Hexavalent Combination Vaccine
Dec 18, 2018

Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq
Nov 11, 2018

ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any cause

* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL
Nov 7, 2018

New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial

* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
Nov 6, 2018

FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis

Show per page

Print
Email page
RSS